Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer Working Group. Ronco G, et al. Among authors: del mistro a. J Natl Cancer Inst. 2006 Jun 7;98(11):765-74. doi: 10.1093/jnci/djj209. J Natl Cancer Inst. 2006. PMID: 16757701 Clinical Trial.
HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology.
Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, Dalla Palma P, Del Mistro A, Gillio-Tos A, Giubilato P, Naldoni C, Polla E, Iossa A, Zorzi M, Confortini M, Giorgi-Rossi P; NTCC working group. Ronco G, et al. Among authors: del mistro a. Eur J Cancer. 2007 Feb;43(3):476-80. doi: 10.1016/j.ejca.2006.11.013. Epub 2007 Jan 12. Eur J Cancer. 2007. PMID: 17223540
Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N; New Technologies for Cervical Cancer Screening Working Group. Ronco G, et al. Among authors: del mistro a. J Natl Cancer Inst. 2008 Apr 2;100(7):492-501. doi: 10.1093/jnci/djn065. Epub 2008 Mar 25. J Natl Cancer Inst. 2008. PMID: 18364502 Clinical Trial.
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J; New Technologies for Cervical Cancer screening (NTCC) Working Group. Ronco G, et al. Among authors: del mistro a. Lancet Oncol. 2010 Mar;11(3):249-57. doi: 10.1016/S1470-2045(09)70360-2. Epub 2010 Jan 18. Lancet Oncol. 2010. PMID: 20089449 Clinical Trial.
HPV testing is an efficient management choice for women with inadequate liquid-based cytology in cervical cancer screening.
Giorgi Rossi P, Carozzi F, Collina G, Confortini M, Dalla Palma P, De Lillo M, Del Mistro A, Ghiringhello B, Gillio-Tos A, Maioli P, Pellegrini A, Schiboni ML, Segnan N, Zaffina LM, Zorzi M, Ronco G; NTCC Working Group. Giorgi Rossi P, et al. Among authors: del mistro a. Am J Clin Pathol. 2012 Jul;138(1):65-71. doi: 10.1309/AJCP6J2OEFOYTRFD. Am J Clin Pathol. 2012. PMID: 22706859 Clinical Trial.
Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi-Rossi P, Segnan N, Cuzick J, Ronco G; NTCC working group. Carozzi F, et al. Among authors: del mistro a. Lancet Oncol. 2013 Feb;14(2):168-76. doi: 10.1016/S1470-2045(12)70529-6. Epub 2012 Dec 21. Lancet Oncol. 2013. PMID: 23261355 Clinical Trial.
Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M, Del Mistro A, Farruggio A, de'Bartolomeis L, Frayle-Salamanca H, Baboci L, Bertazzo A, Cocco P, Fedato C, Gennaro M, Marchi N, Penon MG, Cogo C, Ferro A. Zorzi M, et al. Among authors: del mistro a. BJOG. 2013 Sep;120(10):1260-7; discussion 1267-8. doi: 10.1111/1471-0528.12272. Epub 2013 Jun 21. BJOG. 2013. PMID: 23786222
Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.
Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group. Gillio-Tos A, et al. Among authors: del mistro a. J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26. J Clin Microbiol. 2013. PMID: 23804385 Free PMC article. Clinical Trial.
133 results